scholarly journals The experience of sibutramine administration in patients with obesity and controlled arterial hypertension

2019 ◽  
Vol 16 (2) ◽  
pp. 42-48
Author(s):  
Elena Y. Shupenina ◽  
Elena N. Yushchuk ◽  
Yury A. Vasyuk ◽  
Svetlana V. Yureneva ◽  
Anastasia V. Dubrovina
Keyword(s):  
Weight Loss ◽  
Arterial Hypertension ◽  
Blood Pressure Measurement ◽  
Visceral Adiposity ◽  
Epicardial Fat ◽  
Anthropometric Measurement ◽  
Epicardial Fat Thickness ◽  
Fat Thickness ◽  
Treatment Of Obesity

BACKGROUND: Obesity is a metabolic disorder that becomes epidemic. Visceral adiposity increases the risk of arterial hypertension, diabetes mellitus and other comorbidities. According to this, the main aim of obesity treatment is not only a weight loss but also a decrease of the risk of comorbidities. AIMS: to assess the efficiency and safety of sibutramine in patients with obesity and arterial hypertension, to evaluate the drug influence on epicardial fat thickness. MATERIALS AND METHODS: 57 patients aged 35-60 with obesity and arterial hypertension were included in the study. All patients at the beginning and after 7 months of follow-up underwent complex examination including anthropometric measurement, ECG, office and ambulatory blood pressure measurement, echocardiography. Patients with controlled arterial hypertension were included. During the first month of follow-up patients were given general weight loss recommendations. Then sibutramine was added. Control visits to assess efficiency and safety of drug treatment were held after 1 and 6 months of follow-up. RESULTS: Women predominated among the study participants. Visceral adiposity was approved by anthropometric measurements among all patients. Most patients had impaired left ventricle geometry: concentric remodeling or hypertrophy. During the first month of follow-up the weight loss was mild: 2 kg (less than 2%) in average. Sibutramine for 1 month the weight loss increased: 3.7 kg (more than 2%) in average. After 6 months of drug administration the weight loss of patients consisted 8.6 kg (6.2%) in average. According to echocardiography results indexed mass of LV myocardium decreased in all patients more significantly in women. Also in this group of patients significant decrease of epicardial fat thickness was revealed. Adverse events of sibutramine were revealed in 26.3% of patients. The most frequent were constipation (12.3%) and dry mouth (10.6%). The severity of symptoms persisted for 1 month and then decreased, additional therapy was not required. CONCLUSIONS: Sibutramine treatment of obesity promotes effective weight loss, influences the adipose tissue distribution, decreases the progress of associated comorbidities. Sibutramine is an effective and safe drug that can be used in patients with visceral adiposity and controlled arterial hypertension.

P2595The role of epicardial fat thickness and other parameters of visceral adiposity in right ventricular diastolic function in patients with metabolic syndrome

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
E Sedaia ◽  
V Revenco
Keyword(s):  
Metabolic Syndrome ◽  
Diastolic Dysfunction ◽  
Diastolic Function ◽  
Tricuspid Valve ◽  
Tissue Doppler ◽  
Visceral Adiposity ◽  
Epicardial Fat ◽  
Epicardial Fat Thickness ◽  
Fat Thickness

Abstract Background Abdominal obesity is associated with an increased risk of cardiovascular disease and all-cause mortality especially in patients with metabolic syndrome (MetS). Despite the undeniable importance of right ventricle (RV) function, little is known about RV diastolic function implication in obesity and MetS. Purpose The objective of our study was to evaluate the role of epicardial fat thickness (EFT) and other parameters of visceral obesity in diastolic function of RV in patients with MetS. Methods The study included 70 subjects with MetS (mean age 52.6±9.4 years) and 70 controls without MetS (mean age 53.8±7.5 years). MetS was defined by ≥3 criteria of International Diabetes Federation and American Heart Association/National Heart, Lung, and Blood Institute. We assessed RV diastolic function by pulsed wave and tissue Doppler echocardiography and determined the ratio of early (TV E) and late (TV A) trans-tricuspid valve inflow velocities (TV E/A), early tricuspid valve (TV) annular tissue Doppler velocity (TV e'), the TV E/e' ratio and TV deceleration time (DT). Anthropometric and sonographic parameters of visceral adiposity included: waist circumference (WC), waist-to-hip ratio (WHR), visceral adiposity index (VAI), intraabdominal fat thickness (IFT), abdominal wall fat index (AWFI) and epicardial fat thickness (EFT). Results Mean values of WC (p=0.030), WHR (p=0.008), VAI (p=0.001), IFT (p=0.035), AWFI (p=0.013) and EFT (p=0.012) were significantly higher in the group with MetS vs. controls. RV diastolic function parameters were also significantly changed in the group with MetS vs controls (tab.1). TV E/e' was positively correlated with WC (r=0.297, p<0.01), WHR (r=0.238, p<0.05), VAI (r=0.271, p<0.05), IFT (r=0.556, p<0.01), AWFI (r=0.604, p<0.01) and EFT (r=0.795, p<0.01). Using multivariate regression analysis EFT, WC and plasma glucose level were the most important predictors for RV diastolic dysfunction in subjects with MetS (p<0.05 for all parameters). Table 1. RV diastolic function Variables MetS (n=70) Controls (n=70) p TV E, cm/s 48±11.1 52.1±14 0.025 TV A, cm/s 56.54±11 52.3±11.7 0.034 TV E/A 0.92±0.4 1.07±0.44 0.029 TV e', cm/s 10.6±2.7 10.7±3.5 0.001 TV E/e' 5.84±1.04 4.59±0.82 0.001 DT, ms 227.9±12.4 217±17.8 0.009 Conclusion Our findings support that EFT and WC play an important role in RV diastolic dysfunction in patients with MetS.

Study of epicardial fat thickness as a marker of visceral adiposity in patients with hypothyroidism

2017 ◽  
Vol 14 (1) ◽  
pp. 12
Author(s):  
Ritu Karoli ◽  
Nikhil Gupta ◽  
Jalees Fatima ◽  
Zeba Siddiqi
Keyword(s):  
Visceral Adiposity ◽  
Epicardial Fat ◽  
Epicardial Fat Thickness ◽  
Fat Thickness

scholarly journals Substantial Changes in Epicardial Fat Thickness After Weight Loss in Severely Obese Subjects

Obesity ◽  
2008 ◽  
Vol 16 (7) ◽  
pp. 1693-1697 ◽  
Author(s):  
Gianluca Iacobellis ◽  
Navneet Singh ◽  
Sean Wharton ◽  
Arya M. Sharma
Keyword(s):  
Weight Loss ◽  
Epicardial Fat ◽  
Epicardial Fat Thickness ◽  
Severely Obese ◽  
Obese Subjects ◽  
Fat Thickness

scholarly journals Epicardial Fat Thickness as a Diagnostic Marker of Coronary Lesions in Stable Angina Pectoris Patients

2021 ◽  
Author(s):  
Ulzim Fajar ◽  
Mefri Yanni ◽  
Muhammad Syukri
Keyword(s):  
Adipose Tissue ◽  
Epicardial Adipose Tissue ◽  
Diagnostic Marker ◽  
Visceral Adiposity ◽  
Epicardial Fat ◽  
Stable Angina Pectoris ◽  
Epicardial Fat Thickness ◽  
Coronary Lesion ◽  
Fat Thickness ◽  
Coronary Lesions

  Background: Abdominal visceral adiposity is a risk factor of cardiovascular diseases. It correlates with increasing level of pro-inflammatory adipokines and cytokines which can induce endothelial dysfunction. Epicardial adipose tissue is considered as true visceral adiposity of the heart. Epicardial adipose tissue have pivotal role than other visceral adiposity because of adjacency to the heart and coronary vessels. This study was aimed to measure the cut off point of epicardial fat thickness as a diagnostic marker for the presence of coronary lesion. Methods: This was an observational analytic study with crossectional comparative design. Data was retrieved prospectively at the Heart Center Dr. M. Djamil Padang from August 2019 to February 2020 in stable angina pectoris patients who underwent coronary angiography. The Epicardial Fat Thickness (EFT) was measured at end-diastole from the Parasternal long axis (PLAX) views of three cardiac cycles on the free wall of the right ventricle on echocardiography examination. Bivariate analysis was used to assess epicardial fat thickness and presence of the coronary lesions using Independent Sample T test. A diagnostic test was performed based on receiver operating curve (ROC) analysis. Results: Patients were diagnosed as CAD group group (n =150; 58,11 ± 8,24 years) and non-CAD group (n = 50; 53,16 ± 9,78 years) based on coronary angiogram result. Epicardial fat thickness was higher in subjects with coronary lesions (3,62 ± 1,03 mm) compared with subjects without coronary lesions (1,55 ± 1,10 mm) with p <0.001. Epicardial fat thickness ≥ 2.835 mm predict the presence of coronary lesion by 82% sensitivity, 86% specificity and 88.9% accuracy based on the AUC value. Conclusions: Abnormal epicardial fat thickness ≥ 2.835 mm can be a good diagnostic marker to detect the presence of coronary lesion. 

Sign in / Sign up

Export Citation Format

Share Document